Expression of ER, PR, and HER-2 Neu and correlation with tumor markers in gall bladder carcinoma

• Published in: Journal of cancer research and therapeutics Vol. 19; no. 5; pp. 1279 - 1287
• Main Authors: Mani, Rishit, Gupta, Amit, Gupta, Sweety, Goyal, Bela, Mishra, Rahul, Tandon, Amoli, Sharma, Oshin, Rohilla, Kusum, Kishore, Sanjeev, Dhar, Puneet
• Format: Journal Article
• Language: English
• Published: Mumbai Wolters Kluwer India Pvt. Ltd 01.07.2023; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd
• Subjects: Biomarkers; Bladder cancer; Cancer; Carcinoma; Development and progression; Drug therapy; Estrogen; Gallbladder cancer; Gallstones; Health aspects; Physiological aspects; Progesterone; Prognosis; Receptors; Tumor markers; India; Estrogen receptor; gallbladder cancer; progesterone receptor Her2/neu; tumor marker
• ISSN: 0973-1482; 1998-4138
• DOI: 10.4103/jcrt.jcrt_1754_21

Background: Females having a large proportion of gallbladder carcinoma (GBC) and a higher incidence of gallstones pointed toward the role of sex hormones in GBC development. In this study, we evaluated the expression of Estrogen receptor (ER), Progesterone receptor (PR), and Her2/neu and their correlation with tumor markers and clinicopathological parameters in the GBC. Methods: A total of 50 patients of GBC and 42 patients in control group undergoing surgery for other conditions were taken. The patient's biopsy sample's paraffin block was tested for ER, PR, and Her2/neu expression by immunohistochemistry. Results: ER and PR had no significant expression in GBC and control group, but Her2/neu had 16% expression in GBC, significantly associated with the degree of differentiation with 62.5% (n-5) being well-differentiated; 75% of Her2/neu positive were in stages III and IV. Her2/neu did not correlate with tumor markers despite expression. Conclusions: Her2/neu amplification is a small step in validating that option so it could be included in the treatment and prognostication of GBC.